-
1
-
-
33747349484
-
Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide
-
DOI 10.1016/j.bmcl.2006.07.030, PII S0960894X06008079
-
Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006;16:5093-5096. (Pubitemid 44247701)
-
(2006)
Bioorganic and Medicinal Chemistry Letters
, vol.16
, Issue.19
, pp. 5093-5096
-
-
Vlahov, I.R.1
Santhapuram, H.K.R.2
Kleindl, P.J.3
Howard, S.J.4
Stanford, K.M.5
Leamon, C.P.6
-
2
-
-
71449112911
-
Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients
-
Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49:1467-1476.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 1467-1476
-
-
Li, J.1
Sausville, E.A.2
Klein, P.J.3
-
3
-
-
9444279605
-
Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery
-
DOI 10.1124/mol.104.003723
-
Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004;66:1406-1414. (Pubitemid 39564767)
-
(2004)
Molecular Pharmacology
, vol.66
, Issue.6
, pp. 1406-1414
-
-
Paulos, C.M.1
Reddy, J.A.2
Leamon, C.P.3
Turk, M.J.4
Low, P.S.5
-
6
-
-
0026752798
-
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues
-
Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-3401.
-
(1992)
Cancer Res
, vol.52
, pp. 3396-3401
-
-
Weitman, S.D.1
Lark, R.H.2
Coney, L.R.3
-
7
-
-
14644392093
-
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
-
DOI 10.1016/j.ab.2004.12.026
-
Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293. (Pubitemid 40312593)
-
(2005)
Analytical Biochemistry
, vol.338
, Issue.2
, pp. 284-293
-
-
Parker, N.1
Turk, M.J.2
Westrick, E.3
Lewis, J.D.4
Low, P.S.5
Leamon, C.P.6
-
8
-
-
0036862058
-
99mTc-based radiopharmaceutical
-
DOI 10.1021/bc0200430
-
Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-1210. (Pubitemid 35420011)
-
(2002)
Bioconjugate Chemistry
, vol.13
, Issue.6
, pp. 1200-1210
-
-
Leamon, C.P.1
Parker, M.A.2
Vlahov, I.R.3
Xu, L.-C.4
Reddy, J.A.5
Vetzel, M.6
Douglas, N.7
-
9
-
-
2642514921
-
99mTc-EC20 for imaging folate receptor-positive tumors
-
Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857-866. (Pubitemid 47618567)
-
(2004)
Journal of Nuclear Medicine
, vol.45
, Issue.5
, pp. 857-866
-
-
Reddy, J.A.1
Xu, L.-C.2
Parker, N.3
Vetzel, M.4
Leamon, C.P.5
-
10
-
-
38649094549
-
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials
-
DOI 10.1200/JCO.2007.13.0344
-
Lara PN Jr, Redman MW, Kelly K, et al.; Southwest Oncology Group. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463-467. (Pubitemid 351171700)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.3
, pp. 463-467
-
-
Lara Jr., P.N.1
Redman, M.W.2
Kelly, K.3
Edelman, M.J.4
Williamson, S.K.5
Crowley, J.J.6
Gandara, D.R.7
|